NASDAQ
No price data available for this timeframe.
Cytokinetics, Incorporated (CYTK) has a free cash flow growth of -2.09% as of Friday, May 29, 2026. This represents a 92.87% increase compared to its 12-month average of -29.23%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.